Adaptive Clinical Trials in Precision Medicine: A Framework for Enhancing Cancer Research and Patient Care

Md Shamsuddin Sultan Khan; Md Haroon Or Rashid; Mohammed Khadeer Ahamed Basheer; Md Mazedul Haq

doi:10.25163/biosciences.515802

Biopharmaceuticals and medical sciences | Online ISSN 3064-9226

REVIEWS (Open Access)

Previous Next Contents Vol 5 (1)

Adaptive Clinical Trials in Precision Medicine: A Framework for Enhancing Cancer Research and Patient Care

Md Shamsuddin Sultan Khan ¹, Md Haroon Or Rashid ², Mohammed Khadeer Ahamed Basheer ³, Md Mazedul Haq ⁴

+ Author Affiliations

Journal of Precision Biosciences 5 (1) 1-8 https://doi.org/10.25163/biosciences.515802

Submitted: 01 January 2023 Revised: 10 February 2023 Published: 12 February 2023

Abstract

Background: Adaptive clinical trials and precision medicine represent a transformative era in medical research, where innovation and personalized approaches converge. This study examines the intersection of these two methodologies, resulting in a new paradigm for improving patient outcomes. Methods: This paper reviews the dynamic nature of adaptive clinical trials, characterized by their flexibility and responsiveness, and explores their synergy with precision medicine. The focus is on how these trials integrate real-time patient data, enabling rapid modifications to treatment strategies based on individual genetic and molecular profiles. Results: The fusion of adaptive trials and precision medicine creates unprecedented opportunities in medical research. Adaptive trials allow real-time adjustments based on new findings, while precision medicine provides the framework for targeting interventions to specific genetic signatures, enhancing treatment efficacy. Conclusion: The integration of adaptive clinical trials with precision medicine offers a new frontier in healthcare. By combining adaptability with personalization, this approach enables tailored medical interventions that maximize patient outcomes.

Keywords: Adaptive clinical trials, Precision medicine, Personalized treatment, Targeted therapies

References

Adam, M. (2010). Multi-level complexities in technological development: Competing strategies for drug discovery. In Science in the Context of Application (pp. 67-83). Dordrecht: Springer Netherlands.

Barker, A. D., Sigman, C. C., Kelloff, G. J., Hylton, N. M., Berry, D. A., & Esserman, L. (2019). I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clinical Pharmacology & Therapeutics, 86(1), 97-100.

Berry, D. A. (2011). Adaptive clinical trials: the promise and the caution. Journal of Clinical Oncology, 29(6), 606-609.

Berry, D. A. (2012). Adaptive clinical trials in oncology. Nature reviews Clinical oncology, 9(4), 199-207.

Berry, D. A., Herbst, R. S., & Rubin, E. H. (2012). Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clinical Cancer Research, 18(3), 638-644.

Calvert, M. J., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A. W., & King, M. T. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA, 319(5), 483-494.

Desmond-Hellmann, S. (2012). Toward precision medicine: a new social contract?. Science translational medicine, 4(129), 129ed3-129ed3.

Douillard, J. Y., Shepherd, F. A., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., ... & Kim, E. S. (2010). Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J clin Oncol, 28(5), 744-752.

Esserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., ... & Hylton, N. (2012). Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology, 30(26), 3242.

Fang, F. C., & Casadevall, A. (2010). Lost in translation—basic science in the era of translational research. Infection and immunity, 78(2), 563-566.

Fishburn, C. S. (2013). Translational research: the changing landscape of drug discovery. Drug discovery today, 18(9-10), 487-494.

Freidlin, B., McShane, L. M., Korn, E. L. (2010). Randomized Clinical Trials with Biomarkers: Design Issues. Journal of the National Cancer Institute, 102(3), 152-160.

Gannedahl, M., Udechuku, A., & Bending, M. W. (2018). Initiatives driving accelerated access to medicines in Europe: review of recent concepts and developments. Medicine Access@ Point of Care, 2, 2399202618761854.

Garralda, E., Dienstmann, R., Piris-Giménez, A., Braña, I., Rodon, J., & Tabernero, J. (2019). New clinical trial designs in the era of precision medicine. Molecular oncology, 13(3), 549-557.

Gaydos, B., Anderson, K. M., Berry, D., Burnham, N., Chuang-Stein, C., Dudinak, J., ... & Krams, M. (2009). Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal, 43(5), 539-556.

Geisbert, T. W. (2017). First Ebola virus vaccine to protect human beings?. The Lancet, 389(10068), 479-480.

Gold, K. A., Kim, E. S., Lee, J. J., Wistuba, I. I., Farhangfar, C. J., & Hong, W. K. (2011). The BATTLE to personalize lung cancer prevention through reverse migration. Cancer prevention research, 4(7), 962-972.

Haeusermann, T., Greshake, B., Blasimme, A., Irdam, D., Richards, M., Vayena, E., ... & Strech, D. (2019). Open sharing of genomic data: Who does it and why?. PLoS ONE, 14(5), e0209485.

Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., ... & Kieny, M. P. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet, 389(10068), 505-518.

Hylton, N. M., Blume, J. D., Bernreuter, W. K., Pisano, E. D., Rosen, M. A., Morris, E. A., ... & Schnall, M. D. (2012). Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology, 263(3), 663-672.

Jadreškic, D. (2021). Prilagodba za translaciju–prilagodljiva klinicka ispitivanjai biomedicinske inovacije. European Journal of Analytic Philosophy, 17(2), S3-24.

Jaki, T., & Uptegrove, D. (2019). Advanced statistical approaches for adaptive clinical trials. Statistics in Medicine, 38(3), 366-383.

Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein Jr, G. R., Tsao, A., ... & Hong, W. K. (2011). The BATTLE trial: personalizing therapy for lung cancer. Cancer discovery, 1(1), 44-53.

Kim, E. S., Hirsh, V., Mok, T., Socinski, M. A., Gervais, R., Wu, Y. L., ... & Douillard, J. Y. (2018). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet, 372(9652), 1809-1818.

Lipsky, A. M., & Lewis, R. J. (2013). Response-adaptive decision-theoretic trial design: operating characteristics and ethics. Statistics in medicine, 32(21), 3752-3765.

London, A. J., & Kimmelman, J. (2020). Against pandemic research exceptionalism. Science, 368(6490), 476-477.

Longini, I. M., Røttingen, J. A., Kieny, M. P., Edmunds, W. J., & Henao-Restrepo, A. M. (2018). Questionable efficacy of the rVSV-ZEBOV Ebola vaccine–Authors' reply. The Lancet, 391(10125), 1021-1022.

Lu, T. S., & Lee, Y. Y. (2019). The development of cost-effective genotyping technologies: A case study from The National Academies Keck Futures Initiative. Frontiers in Genetics, 10, 352.

Mahlich, J., Bartol, A., & Dheban, S. (2021). Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry?-a scenario analysis. Health Economics Review, 11(1), 1-10.

Massard, C., Michiels, S., Ferté, C., Le Deley, M. C., Lacroix, L., Hollebecque, A., ... Soria, J. C. (2017). High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discovery, 7(6), 586-595.

Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., ... & Fukuoka, M. (2019). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-957.

National Research Council. (2011). Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease.

Nelson, N. J. (2010). Adaptive clinical trial design: has its time come?.

Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., ... & Jaki, T. (2018). Adaptive designs in clinical trials: why use them, and how to run and report them. BMC medicine, 16, 1-15.

Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature reviews Drug discovery, 10(6), 428-438.

Quinlan, J., Gaydos, B., Maca, J., & Krams, M. (2010). Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clinical trials, 7(2), 167-173.

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., ... & Taron, M. (2019). Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine, 361(10), 958-967.

Solomon, M. (2015). Making medical knowledge. Oxford University Press.

Steel, D. (2010). Epistemic values and the argument from inductive risk. Philosophy of science, 77(1), 14-34.

Taylor, D. (2015). The pharmaceutical industry and the future of drug development.

Thorlund, K., Haggstrom, J., Park, J. J., & Mills, E. J. (2018). Key design considerations for adaptive clinical trials: a primer for clinicians. bmj, 360.

Upshur, R., & Fuller, J. (2016). Randomized controlled trials in the West African Ebola virus outbreak. Clinical Trials, 13(1), 10-12.

Varghese, J. (2021). Influence and prioritization of non-epistemic values in clinical trial designs: a study of Ebola ça Suffit trial. Synthese, 198(Suppl 10), 2393-2409.

Varghese, J. (2021). Non-epistemic values in shaping the parameters for evaluating the effectiveness of candidate vaccines: the case of an Ebola vaccine trial. History and Philosophy of the Life Sciences, 43(2), 63.

Vogenberg, F. R., Barash, C. I., & Pursel, M. (2010). Personalized medicine: part 1: evolution and development into theranostics. Pharmacy and Therapeutics, 35(10), 560.

Wilholt, T. (2019). Bias and values in scientific research. Studies in History and Philosophy of Science Part A, 40(1), 92-101.

Woodcock, J., & LaVange, L. M. (2017). Master protocols to study multiple therapies, multiple diseases, or both. New England Journal of Medicine, 377(1), 62-70.

Yarla, N. S., Bishayee, A., Sethi, G., Reddanna, P., Kalle, A. M., Dhananjaya, B. L., ... & Duddukuri, G. R. (2016, October). Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. In Seminars in cancer biology (Vol. 40, pp. 48-81). Academic Press.

Abstract
Export Citation

View Dimensions

View Plumx

View Altmetric

Save

0
Citation

179
View

Share